Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6335455 | 1.00 | TACR1 (0.55) | TACR1SIGMAR1LTA4HBACE1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6541504 | 0.99 | TACR1 (0.56) | TACR1SIGMAR1LTA4HBACE1ALDH1A1 | |
| SCHEMBL310284 | 0.87 | SIGMAR1 (0.51) | TACR1SIGMAR1LTA4HBACE1ALDH1A1 | |
| SCHEMBL14085915 | 0.87 | SIGMAR1 (0.51) | TACR1SIGMAR1LTA4HBACE1ALDH1A1 | |
| SCHEMBL1189622 | 0.87 | SIGMAR1 (0.51) | TACR1SIGMAR1LTA4HBACE1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11446780 | 0.84 | SIGMAR1 (0.49) | TACR1SIGMAR1LTA4HBACE1ALDH1A1 | |
| SCHEMBL29289212 | 0.84 | SIGMAR1 (0.49) | TACR1SIGMAR1LTA4HBACE1ALDH1A1 | |
| SCHEMBL10675682 | 0.84 | SIGMAR1 (0.49) | TACR1SIGMAR1LTA4HBACE1ALDH1A1 | |
| SCHEMBL24803412 | 0.84 | SIGMAR1 (0.51) | TACR1SIGMAR1LTA4HBACE1ALDH1A1 | |
| SCHEMBL5201106 | 0.83 | SIGMAR1 (0.47) | TACR1SIGMAR1LTA4HBACE1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171350-A1 | Benzhydryl derivatives | FUJISAWA PHARAMACEUTICAL CO., LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| US-20040220403-A1 | 1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-04 | — | — | US | disclosed |
| EP-1456201-A1 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-15 | — | — | EP | disclosed |
| EP-1368343-A1 | 1-(2-METHOXYBENZYL)-3-BENZHYDRYLPIPERAZINES AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | disclosed |
| WO-2003053957-A1 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2002055518-A1 | 1-(2-METHOXYBENZYL)-3-BENZHYDRYLPIPERAZINES AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171350-A1 | Benzhydryl derivatives | BDKRB1, BDKRB2, TACR1 | TACR1 3/4885SIGMAR1 863/4885LTA4H 639/4885 |
| US-20040220403-A1 | 1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonists | BDKRB1, BDKRB2, TACR1 | TACR1 3/4885SIGMAR1 458/4885LTA4H 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.